Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Narendra Revanuri
Observed name:
Narendra Revanuri
Institution:
Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology
Observed institution:
Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology
ORCID:
0009-0004-3295-9731
Observed ORCID:
0009-0004-3295-9731
OpenAlex ID:
A5118384162
Organometallic Compound’s Phototoxicity Against Cancer Cells
2025
·
C. Hazarathaiah Yadav
, Narendra Revanuri
, et al.
·
Biomedical Engineering Applications Basis and Communications
·
12
A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs
2025
·
A. Mohamed Sikkander
, C. Hazarathaiah Yadav
, et al.
·
World Journal of Applied Medical Sciences
·
8
Current Developments in Cyclophosphamide for Lymphoma: Immunomodulation, Metronomic Approaches, and Toxicity Control
2025
·
A. Mohamed Sikkander
, C. Hazarathaiah Yadav
, et al.
·
World Journal of Applied Medical Sciences
·
8
Current Trends: Recent Innovation and Impacts of Flap Necrosis in Breast Reduction
2025
·
A. Mohamed Sikkander*
, C. Hazarathaiah Yadav
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
6
Recent Trends in Oncovin (Vincristine) Use for Acute Lymphoblastic Leukemia: Liposomal Formulations, Pharmacogenomics, and Toxicity-Mitigation Strategies
2025
·
A. Mohamed Sikkander*
, C. Hazarathaiah Yadav
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
2
Show more works
View as search
Works count:
5
Citation count:
36
H-index:
4
I10-index:
1
Year
Topic
Type